KalshiFinancials
FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026)
FDA decision on Anitocabtagene Autoleucel (anito-cel) in 2026
Ends Jan 1, 2027
Bet NowDisclosure
18+ only. Event contracts carry significant risk and are not suitable for everyone, you can lose the entire amount you commit. Not available in all jurisdictions; restrictions and eligibility requirements apply.
- a full approval or an accelerated approval858.7 VOL.——
Rules Summary
If the FDA's decision on Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences in 2026 is a full approval or an accelerated approval, the market resolves to Yes.
Timeline and Payout
- Opened
- Jun 17, 2026, 9:30 PM
- Closes
- Jan 1, 2027, 4:59 AM
- Pays out
- 0.5 hours after close
Series KXANITOCABTAGENE · Event KXANITOCABTAGENE-27 · Market KXANITOCABTAGENE-27-Y